1 Ideal Buy From 23 "Safer" April Dividend Dogs In 50 Fortune World's Most Admired Companies (FWMAC)Seeking Alpha • 04/04/25
TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritisPRNewsWire • 04/04/25
Potatoes, discount chains and drugmakers offer havens in stock-market bloodbathMarket Watch • 04/03/25
Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience LeadershipBusiness Wire • 04/02/25
S&P 500 Gains and Losses Today: Johnson & Johnson Drops as Judge Rejects Liability SettlementInvestopedia • 04/01/25
Johnson & Johnson Announces Expected Closing Date for Intra-Cellular AcquisitionBusiness Wire • 04/01/25
S&P, Nasdaq rise as investors await US tariff clarity; Johnson & Johnson slips, PVV Corp jumpsInvezz • 04/01/25
Johnson & Johnson shares fall as US judge rejects $10B talc settlement planProactive Investors • 04/01/25
Judge rejects Johnson & Johnson's $10B settlement to end baby powder lawsuitsNew York Post • 04/01/25
J&J Dives After Judge Tosses Out $10 Billion Talc-Based Bankruptcy PlanInvestors Business Daily • 04/01/25
US Judge Rejects Another Johnson & Johnson Attempt To Use Bankruptcy For Talc Cancer ClaimsBenzinga • 04/01/25
Federal Judge Rejects Johnson & Johnson Bankruptcy Strategy, Paving Way for Talc Victims to Seek Justice in Trial CourtsBusiness Wire • 04/01/25